이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 비소세포폐암(NSCLC) 참가자를 대상으로 선별된 면역요법 조합에 대한 1b/2상 플랫폼 연구

2026년 11월 9일 업데이트: Servier Bio-Innovation LLC

PD-L1 발현이 높은 이전 치료 경험이 없는 진행성 비소세포폐암(NSCLC) 성인 참가자를 대상으로 선별된 면역요법 조합에 대한 1b/2상, 다기관, 공개 라벨 플랫폼 연구

This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

102

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Taipei, 대만, 100225
        • National Taiwan University Hospital
      • Taipei, 대만, 114202
        • Tri-Service General Hospital
      • Cluj-Napoca, 루마니아
        • Inst Oncologic "Prof Dr I Chiricuta" Cluj Napoca
    • Michigan
      • Detroit, Michigan, 미국, 48202
        • Henry Ford Health
    • Ohio
      • Canton, Ohio, 미국, 44718
        • Gabrail Cancer Center
      • Columbus, Ohio, 미국, 43210
        • Ohio State University Comprehensive Cancer Center
      • Hasselt, 벨기에, 3500
        • Jessa Ziekenhuis
      • Barretos, 브라질, 14784-400
        • Hospital de Amor - Barretos
      • Chapecó, 브라질, 89812618
        • Supera Oncologia
      • Curitiba, 브라질, 80810-050
        • CIONC
      • Natal, 브라질, 59035-055
        • Liga Contra O Cancer - Natal
      • Porto Alegre, 브라질, 90020-090
        • Santa Casa de Porto Alegre
      • Porto Alegre, 브라질, 90619-900
        • Hospital São Lucas Da Pucrs
      • Rio de Janeiro, 브라질, 22250-905
        • Oncoclinicas Rj
      • São Paulo, 브라질, 01509-010
        • Hospital A C Camargo
      • São Paulo, 브라질, 03102-002
        • Hospital São Camilo
      • São Paulo, 브라질, 04538-132
        • Oncoclinicas Sp
      • São Paulo, 브라질, 05652-900
        • Hospital Albert Einstein
      • Barcelona, 스페인, 08035
        • Vall D' Hebron Institute of Oncology (Vhio), University Hospital
      • Madrid, 스페인, 28007
        • Hospital General Universitario Gregorio Marañón
      • Madrid, 스페인, 28027
        • Clinica Universitaria de Navarra (Madrid)
      • Madrid, 스페인, 28050
        • Hospital Univ. Hm Sanchinarro Start Ciocc Early Phase
      • Málaga, 스페인, 29010
        • Hospital Universitario Virgen de La Victoria
      • Valencia, 스페인, 46026
        • Hospital Universitario Y Politecnico La Fe
      • London, 영국, SW3 6JJ
        • The Royal Marsden in Chelsea
      • London, 영국, SM2 5PT
        • The Royal Marsden in Sutton
      • Manchester, 영국, M20 4BX
        • The Christie Nhs Foundation Foundation Trust
      • Sankt Pölten, 오스트리아, 3100
        • Universitatsklinikum St. Poelten
      • Vienna, 오스트리아, 1090
        • Medical University of Vienna - Akh
      • Aviano, 이탈리아, 33081
        • Centro Di Riferimento Oncologico
      • Meldola, 이탈리아, 47014
        • Inst. Romagnolo Per Lo Studio E La Cura Dei Tumori
      • Milan, 이탈리아, 20162
        • ASST Grande Ospedale Metropolitano Niguarda
      • Milan, 이탈리아, 20133
        • Irccs Fondazione Istituto Nazionale Dei Tumori
      • Milan, 이탈리아, 20141
        • Istituto Europeo Di Oncologia
      • Naples, 이탈리아, 80131
        • Ist. Nazionale Tumori Irccs Fondazione G Pascale
      • Perugia, 이탈리아, 06132
        • Azienda Ospedaliera S. Maria Della Misericordia
      • Roma, 이탈리아, 00144
        • Istituto Nazionale Tumori Regina Elena
      • Rozzano, 이탈리아, 20089
        • Istituto Clinico Humanitas I.R.C.C.S
      • Dijon, 프랑스, 21079
        • Centre Georges Francois Leclerc
      • Grenoble, 프랑스, 38043
        • Chu Grenoble Alpes
      • Marseille, 프랑스, 13009
        • Institut Paoli Calmette
      • Saint-Herblain, 프랑스, 44805
        • Centre René Gauducheau/Inst de Cancér. de L'Ouest
      • Villejuif, 프랑스, 94805
        • Institut Gustave Roussy
      • Farkasgyepű, 헝가리, 8582
        • Farkasgyepu Tudogyogyintezet
      • Gyöngyös, 헝가리, 3200
        • Bugat Pal Hospital
      • Pécs, 헝가리, 7624
        • Pecsi Tudomanyegyetem, Klinikai Kozpont
      • Albury, 호주, 2640
        • Border Medical Oncology Research Unit
      • Bedford Park, 호주, 5042
        • Flinders Medical Centre
      • St Albans, 호주, 3021
        • Sunshine Hospital
      • Traralgon, 호주, 3844
        • Latrobe Regional Health
      • Hong Kong, 홍콩
        • Queen Mary Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adult patient aged ≥ 18 years
  • Written informed consent
  • Histologically (squamous or non-squamous) or cytologically documented locally advanced NSCLC not eligible for surgical resection and/or definitive chemoradiation, or metastatic NSCLC
  • No prior systemic treatment for locally advanced or metastatic NSCLC
  • High tumor cell PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] based on documented status as determined by an approved test
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Measurable disease as determined by RECIST v1.1

Exclusion Criteria:

  • Tumors harboring driver mutations/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations)
  • Prior immune checkpoint inhibitor therapy
  • Active brain metastases
  • Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  • Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll
  • Active, known or suspected autoimmune disease or immune deficiency
  • History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP) and other monoclonal antibody (mAbs) and/or their excipients
  • History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2
  • History of inflammatory bowel disease or colitis ≥ grade 2
  • History of hemophagocytic lymphohistiocytosis.
  • Systemic chronic steroid therapy (>10mg/d prednisone or equivalent)
  • Clinically significant infection, as assessed by the investigator
  • Pregnant or breast-feeding (lactating) women
  • Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant)
  • Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: S095018 (anti-TIM3 antibody) in combination with cemiplimab

Part A: Combination-therapy safety lead-in

Via IV infusion on Day 1 of each 21-day cycle

350 mg via IV infusion on Day 1 of each 21-day cycle

실험적: S095024 (anti-CD73 antibody) in combination with cemiplimab

Part A: Combination-therapy safety lead-in

350 mg via IV infusion on Day 1 of each 21-day cycle

Via IV infusion on Day 1 of each 21-day cycle

실험적: S095029 (anti-NKG2A antibody) in combination with cemiplimab

Part A: Combination-therapy safety lead-in

350 mg via IV infusion on Day 1 of each 21-day cycle

Via IV infusion on Day 1 of each 21-day cycle

실험적: S095018 (anti-TIM3 antibody) RDE in combination with cemiplimab

Part B: Randomized dose expansion

350 mg via IV infusion on Day 1 of each 21-day cycle

Via IV infusion on Day 1 of each 21-day cycle

실험적: S095024 (anti-CD73 antibody) RDE in combination with cemiplimab

Part B: Randomized dose expansion

350 mg via IV infusion on Day 1 of each 21-day cycle

Via IV infusion on Day 1 of each 21-day cycle

실험적: S095029 (anti-NKG2A antibody) RDE in combination with cemiplimab

Part B: Randomized dose expansion

350 mg via IV infusion on Day 1 of each 21-day cycle

Via IV infusion on Day 1 of each 21-day cycle

활성 비교기: Cemiplimab (control arm)

Part B: Randomized dose expansion

350 mg via IV infusion on Day 1 of each 21-day cycle

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence and severity of dose-limiting toxicities (DLTs) during the first 2 cycles of combination treatment
기간: Through the end of the Cycle 2 (each cycle is 21 days)

Part A

Through the end of the Cycle 2 (each cycle is 21 days)
Incidence and severity of adverse events (AEs)
기간: From the signed informed consent form (ICF) to 30 days after the last dose

Part A

From the signed informed consent form (ICF) to 30 days after the last dose
Incidence and severity of serious adverse events (SAEs)
기간: From the signed ICF to 120 days after the last dose

Part A

From the signed ICF to 120 days after the last dose
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
기간: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

Part A

From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation
기간: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

Part A

From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
Objective Response (OR)
기간: Until study termination (approximately 2 years)

Part B: Participants who achieve complete response (CR) or partial response (PR), as per investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Until study termination (approximately 2 years)

2차 결과 측정

결과 측정
측정값 설명
기간
Objective Response (OR)
기간: Until study termination (approximately 3 years)

Part A: Participants who achieve CR or PR, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

Until study termination (approximately 3 years)
Best Overall Response (BOR)
기간: Until study termination (approximately 3 years)

Part A and B: The best response designation using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST), recorded between the date of the first dose of treatment and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. CR or PR used in the BOR requires a confirmation that is at least 4 weeks apart.

Until study termination (approximately 3 years)
Duration of Response (DoR)
기간: Until study termination (approximately 3 years)

Part A and B: The time from the first documentation of CR or PR until the documented progressive disease (PD) or death, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

Until study termination (approximately 3 years)
Disease Control (DC)
기간: Until study termination (approximately 3 years)

Part A and B: Participants who achieved stable disease (SD), PR, or CR (based on participant's best response), as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

Until study termination (approximately 3 years)
6-month Durable Response (6-month DR)
기간: Until study termination (approximately 3 years)

Part A and B: Continuous CR or PR for ≥ 6 months, recorded between the date of the first dose of treatment and the date of the first objectively documented progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or the date of subsequent anti-cancer therapy, whichever occurs first.

Until study termination (approximately 3 years)
Progression-Free Survival (PFS)
기간: Until study termination (approximately 3 years)

Part A and B: The time from the first dose to the first documented PD or death due to any cause, whichever occurs first, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator.

Until study termination (approximately 3 years)
Plasma or serum concentration of S095018
기간: From first dose to 30 days after the last dose

Part A and B

From first dose to 30 days after the last dose
Plasma or serum concentration of S095024
기간: From first dose to 30 days after the last dose

Part A and B

From first dose to 30 days after the last dose
Plasma or serum concentration of S095029
기간: From first dose to 30 days after the last dose

Part A and B

From first dose to 30 days after the last dose
Incidence and titer of anti-drug antibodies (ADA) directed against S095018
기간: From screening to 90 days after the last dose

Part A and B

From screening to 90 days after the last dose
Incidence and titer of anti-drug antibodies (ADA) directed against S095024
기간: From screening to 90 days after the last dose

Part A and B

From screening to 90 days after the last dose
Incidence and titer of anti-drug antibodies (ADA) directed against S095029
기간: From screening to 90 days after the last dose

Part A and B

From screening to 90 days after the last dose
Incidence and severity of adverse events (AEs)
기간: From signed ICF to 30 days after the last dose

Part B

From signed ICF to 30 days after the last dose
Incidence and severity of serious adverse events (SAEs)
기간: From signed ICF to 120 days after the last dose

Part B

From signed ICF to 120 days after the last dose
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
기간: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

Part B

From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation
기간: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

Part B

From signed ICF through treatment discontinuation (up to 108 weeks of treatment)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 8월 7일

기본 완료 (추정된)

2027년 4월 1일

연구 완료 (추정된)

2027년 7월 1일

연구 등록 날짜

최초 제출

2023년 11월 29일

QC 기준을 충족하는 최초 제출

2023년 12월 7일

처음 게시됨 (실제)

2023년 12월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

키워드

기타 연구 ID 번호

  • SPLFIO-174

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.

Access can be requested for all interventional clinical studies:

  • used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
  • where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.

In addition, access can be requested for all interventional clinical studies in patients:

  • sponsored by Servier
  • with a first patient enrolled as of 1 January 2004 onwards
  • for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

IPD 공유 기간

After Marketing Authorization in EEA or US if the study is used for the approval.

IPD 공유 액세스 기준

Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .